Undecimal Bio is a Cambridge-based biotechnology company developing targeted delivery technologies for RNA medicines. Spun out of Eleven Therapeutics, the company is addressing a major challenge in RNA therapeutics: delivering a treatment to the intended cells and tissues rather than relying on the therapeutic molecule alone.

Small interfering RNA (siRNA) can be used to silence specific genes, creating opportunities to develop treatments for diseases driven by particular biological mechanisms. However, getting these molecules into the right cells remains a significant challenge. Undecimal Bio is developing its proprietary DELiveri platform, which uses artificial intelligence to identify conjugates that can direct RNA medicines towards defined cell types.

The company is also working to advance its renovascular programmes and expand its research capabilities at laboratories based at the Cancer Research UK Cambridge Institute. Its approach combines computational discovery with the biological research needed to develop targeted therapies.

This article covers:

• Undecimal Bio’s RNA delivery technology and research focus.
• Its October 2026 seed financing.
• The investors supporting the company.
• How funding can support early biotechnology development.
• Lessons for entrepreneurs building science-led businesses.

The October 2026 seed round

On 13 October 2026, Undecimal Bio announced a €16 million seed financing round, equivalent to approximately $18 million. The round was co-led by 4BIO Capital and IQ Capital, with participation from Verve Ventures, Harel Tech, Entree Capital, Kerna Ventures and Saras Capital.

The financing is intended to expand the company’s DELiveri platform, advance its renovascular programmes and grow its research team. The company will continue developing the technology needed to direct RNA-based medicines towards specific cell types.

This is an important stage for a biotechnology business because early financing must support both the development of its core platform and the generation of evidence needed to determine which therapeutic opportunities are most promising.

The round also brings together investors with interests in biotechnology, technology innovation and early-stage companies. For a business developing a specialised drug-delivery platform, attracting investors willing to support research before commercial products are available can be an important step towards longer-term development.

Why targeted delivery matters

RNA-based medicines offer ways to influence gene expression, but their potential depends on whether the therapeutic molecules can reach the appropriate cells. Delivery is therefore a central part of the development process, not simply a technical detail that follows drug discovery.

Undecimal Bio’s DELiveri platform is designed to identify conjugates that can help target RNA medicines to defined cell types. The company is applying this approach to its research programmes while developing the wider technology platform.

The potential value lies in making RNA therapeutics more precisely targetable. However, the October 2026 funding announcement represents support for research and development, not evidence that the platform has already produced approved medicines. Further scientific and clinical work will be required to establish the safety and efficacy of any resulting therapies.

From spin-out to independent development

Undecimal Bio emerged from Eleven Therapeutics, providing a foundation in RNA technology and research. Its seed financing gives the company resources to develop its own platform and advance selected therapeutic programmes.

The round is a private investment financing. The publicly available reporting identifies the participating investors but does not establish a separate grant award as part of the transaction. The disclosed €16 million should therefore be treated as the amount of the seed financing, rather than a complete total of all possible public and private support across the company’s history.

For biotechnology founders, this distinction matters. Equity investment, research grants and other non-dilutive funding can all support innovation, but they have different conditions, implications and reporting requirements.

What Undecimal Bio’s funding journey shows

A clearly defined scientific bottleneck can anchor a business.

Undecimal Bio focuses on targeted delivery, a specific challenge in the development of RNA medicines. Founders should explain why solving their chosen problem could unlock value for customers or patients.

Platform technology can create several development opportunities. 

A delivery platform may support multiple research programmes, although each potential therapy still needs appropriate validation.

Biotechnology needs patient capital. 

Scientific research, preclinical development and clinical testing can require substantial resources before a product reaches the market. Founders need to align their fundraising plans with realistic research milestones.

Spin-outs can build on existing scientific expertise. 

Undecimal Bio’s origins at Eleven Therapeutics illustrate how specialised research can form the basis of a focused new company.

Investor fit matters as much as headline funding. 

Entrepreneurs should seek investors who understand the scientific risks, development timelines and capital requirements of their sector.

For founders in biotech, medtech and other research-intensive fields, Undecimal Bio demonstrates the importance of building a funding strategy around a defined technical challenge, a credible development plan and milestones that can progressively reduce uncertainty.

How Fundingtrip can help entrepreneurs

Biotechnology entrepreneurs must often navigate several funding routes, from specialist venture capital to competitive research and innovation programmes. Understanding which options fit a company’s development stage can help founders plan their capital needs and prepare more focused applications. Fundingtrip’s courses help entrepreneurs build that knowledge and develop their funding strategy. Learn more through Fundingtrip courses.

About the author of this post

.

Sara Gavidia
Content Creator
Communications Manager & Content creator
LinkedIn
[email protected]

.

Hello! I’m Sara 👋🏻

I’m FundingTrip’s Content creator. I write posts about technology, funding and innovation. If you liked this one, subscribe to our newsletter to receive more updates!

Post reviewed by David Arias, funding expert.